Showing posts with label post transplant complications. Show all posts
Showing posts with label post transplant complications. Show all posts

Tuesday, March 10, 2015

Topic Discussion: Renal Vein Thrombosis in the Allograft


Incidence:
0.5%-4% and frequently results in graft loss

Risk factors:
Technique error
Hypovolaemia Atherosclerosis OKT3 (plus high-dose methylprednisolone) Antiphospholipid antibodies High dose steroids Long cold ischaemia time Delayed graft function recovery

Certain renal diseases( membranous GN, SLE)
Antiphospholipid antibody syndrome
Use of oral contraception, 
Hereditary thrombophilia secondary to protein C or factor V deficiency

Clinical presentation:
Acute anuria, hematuria, graft tenderness, primary non function of the graft

Best test:
Renal sonogram with dopplers waveform evaluation( most important part)
A normal renal arterial waveform in either an allograft or native kidney shows antegrade flow throughout the entire cardiac cycle. Reversal of diastolic flow in the allograft renal artery, although not specific, is considered abnormal. This finding is caused by a significant increase in resistance in small intrarenal or large extrarenal vessels. This sign is not pathognomonic for renal vein thrombosis ( as can be seen with ATN or rejection as well).  Renal vein thrombosis was more likely to occur in the acute (24 hours) and perioperative (30 days) periods. It is important to recognize the abnormal duplex Doppler waveform pattern, reversal of diastolic flow, which is associated with renal vein thrombosis.

Treatment: 
Timely returning back to the OR for thrombectomy and or reconstruction of venous component
Streptokinase or urokinase
Percutaneous mechanical thrombectomy and
Localized catheter-directed thrombolysis
But overall, prognosis is poor with many times leading to nephrectomy.

Two great reviews:


Monday, November 14, 2011

Journal Club: Blocking complement prevents antibody mediated rejection in positive crossmatch living donor transplantation.


In an exciting pilot study published this month in AJT, Stegall et al. used Eculizumab, a C5 inhibitor, to prevent antibody mediated rejection (AMR) in positive crossmatch living donor transplantation.
High titers of donor specific antibody bind to the cell surface and activate complement through the classical pathway.  Cleavage of C5 precedes the formation of the MAC complex; therefore blocking C5 should inhibit complement mediated cell lysis.  Eculizumab is a monoclonal antibody FDA approved for paroxysmal nocturnal hemoglobinuria with a high affinity for C5.

The authors evaluated patients with donor specific antibody (DSA) described as a B flow cytometry crossmatch with channel shift (semi quantitative measure of antibody strength) between 200 and 450 which was confirmed by Luminex antibody analysis, against their prospective donors.  These patients were either treated with eculizumab (n=26) or a historical control from 2008 - 2010 treated with plasma exchange (n=51).  Both groups received pre-transplant plasma exchange until the channel shift was under 300.  All control patients received post transplant plasmapheresis while only 3 patients in the Eculizumab group received post transplant plasma exchange.  Patients were induced with thymoglobulin.  Protocol biopsies were performed on POD# 7, 14, 28, 90 and 365. 

Eculizumab was dosed as 1200mgs prior to transplantation then 600mgs on POD 1, then weekly for 4 weeks.  At week 4 and 8 weeks crossmatch was repeated and eculizumab was stopped if B cell crossmatch channel shift was below 200.  The primary endpoint of the study was the incidence of antibody mediated rejection in the first 3 months after living donor transplantation. 
Baseline characteristics in both groups including DSA titer were similar.  The incidence of AMR in the first 3 months was 7.7% in the eculizumab group versus 41.2% in the control group, with all cases occurring in the first month.  Graft survival was 100% and 96% respectively.  A similar percentage of patients developed high DSA in both groups during the first 3 months.  All patients in the Eculizumab group had positive C4D staining on protocol biopsy compared to 91% of control patients.    Mean serum creatinine was similar in both groups however, at 1 year 6.7% patients in the eculizumab group had transplant glomerulopathy compared to 36% of control patients.  One patient in the eculizumab group with transplant glomerulopathy was on eculizumab for a full year and lost his graft in 2 years.  One patient has subclinical ACR and one patient developed Burketts lymphoma 2.5 years post transplant.
This study is a truly novel approach to positive crossmatch transplantation, and extends previous reports suggesting efficacy in treating AMR.  While most therapies aim at lowering DSA (plasmapheresis, IVIg, rituximab, velcade), eculizumab simply inhibits the effector pathway of complement.  As the authors point out the study does suffer from limitations.  They included a historical control rather than to perform a randomized trial, and the authors did not evaluate efficacy in donor recipient pairs with a CDC positive T cell crossmatch.  It is also true that despite complement blockade there were patients who still when on to develop AMR and transplant glomerulopathy.  The other obvious question is what will happen 2 or 3 years down the line after eculizumab was stopped?  In addition to therapeutic limitations, the approximate cost of a single dose of eculizumab is about $6,000 dollars making it an extremely expensive therapy.  Regardless of these limitations, this is an exciting study that will hopefully open new doors in treating antibody mediated rejection and facilitate transplantation of highly sensitized individuals.  

Ref:
Post by 
Dr.Vinay Nair
Mt Sinai, Transplant Division
New York, USA

ASN2011: CPC- Adenovirus Nephropathy

One of the highlights of ASN is always the CPC conference. This year the case was a transplant case with viral nephropathy and the nephropathy was Adenoviral origin.



Adenovirus nephropathy

Adenovirus is an important virus to consider in the differential of post kidney and BMT transplant nephropathies.  The urinary subgroup is 34 or 35 and the incidence is < 1% causing nephropathy.
Can see hematuria, testicular tenderness, and subjective complaints.
The kidney biopsy usually has ATN or AIN or abscess.  The viral particles are mostly in the epithelial cells unlike CMV which can infect endothelium and epithelium.  In the EM, there are 70nm non enveloped bodies noted.
Treatment is decreasing immunosuppresion or cidofivir ( nephrotoxic) but may have to be used.
A diagnosis that we should keep in mind when thinking of viral etiologies of nephropathies post transplant. 
Take a look at this recent JASN article.

Ref:

Sunday, November 13, 2011

ASN2011: late breaking trials: RESCUE TRIAL

A trial was presented about looking at Sirolimus(SRL) in primary prevention of skin cancer in kidney transplant recipients.  Patients with history of known skin cancer who had received a kidney transplant were randomized to continue their current CNI based regimen or change to a SRL based regimen.
Use of SRL based regimen showed a 67% risk reduction of skin cancer. Data on post CrCl and proteinuria was not presented. It shows again and again to use that SRL is a very good cancer preventive agent but can it prevent acute rejection episodes and proteinuria is not clear. Data from Canada in mice studies discussed earlier in the Onco Nephrology pre course by Dr. Susan Quaggin shed light on the mTOR pathway. It appears that if the mTOR pathway is completely knocked out in mice, they developed collapsing FSGS and ESRD in 3-4 weeks. Clinically, perhaps SRL doesn't do a complete blockade and hence we don't get such drastic findings but here and there we do hear about the significant proteinuria from SRL.

Ref:
http://www.ncbi.nlm.nih.gov/pubmed/21610495
http://www.ncbi.nlm.nih.gov/pubmed/21792049

Friday, October 28, 2011

Topic Discussion: H1N1 vaccine in Transplantation


An interesting paper by. Katerinis et al. recently investigated the role of vaccination with the adjuvanted H1N1 vaccine in causing the production of anti – HLA antibodies in kidney transplant recipients.
This study was carried out in four cohorts of patients in Switzerland, 92 transplant recipients who had HLA antibodies checked before and 6 weeks after H1N1 vaccine, 59 transplant recipients who had been tested for HLA antibody up to 6 weeks before vaccination then again 4-8 weeks after, patients on the wait list for renal transplantation and a historical cohort from 2008 who never received the H1N1 vaccine.  In the first two cohorts 17.3% and 11.9% of patients developed anti-HLA antibodies (some donor specific while some were not) verses no patients in cohort III and 6.1% of patients in the historical cohort.  Six months after immunization the antibodies disappeared in the majority of patients.  There were two events that could have been attributed to the antibodies: one patient who developed a C4d negative thrombotic angiopathy in the kidney and another patient who developed antibody mediated rejection (however, authors report that he was non-compliant with his immunosuppression).
This is the first study in which antibody responses after H1N1 influenza vaccination led to a significant degree of HLA-antibodies.  The authors point out possible explanations including shared epitopes between influenza hemagglutinin and neuraminidase in the vaccine and HLA proteins, HLA antigens triggering a B-cell response toward the vaccine antigens, nonspecific reactions between vaccine antibodies and the antibody detection assay, and the adjuvanted vaccine triggering allosensitization by stimulating the innate immune system.
Even though there were novo HLA antibodies it is important to note that the authors do not recommend avoiding the vaccination as influenza in the transplant patients can be life threatening and the presence of these de novo antibodies were of low titer and probably not related to clinical events.  However this paper supports further studying the ability of adjuvanted vaccines in causing HLA-antibodies and possibly organ dysfunction.

Ref: I. Katerinis et al: De Novo Anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant 2011;11:1727-1733

Post by Dr.Vinay Nair

Thursday, October 27, 2011

Topic Discussion: Re transplantation after BK Nephropathy

A recent paper in Transplantation ( multi institutional) looked at this exact question. How safe and well do patients when they get a re transplantation of the kidney after failed prior transplant from BK Nephropathy.
This retrospective study evaluated 31 patients from 6 centers.  26/31 had documented clearance of viremia and 13 underwent transplant nephrectomy before the new transplant.  Only 2 patients in the new transplants got BK nephropathy.  7/31 had acute rejection.  The patients who had BK viremia and replications had higher 1 year creatinine.  One graft was lost due to rejection. But overall, majority did well. Based on this small trial, the authors conclude that re transplantation is safe and effective for patients with prior graft loss due to BK Nephropathy but preferably post BK viral clearance.


Take a look at the full article at:
http://www.ncbi.nlm.nih.gov/pubmed/21836535

Wednesday, October 19, 2011

HHV-8 in Transplantation


Ariza-Heredia et al. published an interesting review of HHV8 associated complications in Transplantation this month.  The review, of which the major points are highlighted below, cover the pathogenesis, epidemiology, clinical presentation, diagnosis and treatment, and prevention of HHV-8. 



Pathogenesis of HHV-8
After primary infection HHV-8 establishes latency in CD19 B cells.  It can exist in a latent phase and beinduced to transition to the lytic state.  The trigger of this transition is unknown, however, once in the lytic phase several genes are upregulated increasing the progression of the cell cycle, Bcl-2 protien preventing apoptosis, secretion of IL6 (promotes B-cell proliferation) and angiogenic cytokines which stimulate VEGF. 
Epidemiology and Risk Factors.
Seroprevalence ranges from 4-7% in the U.S. to 5-20% in the Mediterranean and > 50% in zones of Africa and Amazon basin.  The solid organ transplant population in the U.S.  has been shown to have a higher rate of seropositivity (15%).  The chance of developing an HHV-8 related complication is highest among patients from countries with a high seroprevalence rate.  Infection can occur from reactivation of latent infection or primary infection.  Transmitting via organ transplant has also been reported. 
Clinical presentation
Primary infection in immunocompromised patients is often characterized by fever, splenomegaly, rash, lymphoid hyperplasia and pancytopenia – similar to many other viral infections.  Other classically associated diseases include Kaposi’s Sarcoma, Primary Effusion Lymphoma  (PEL)and Castleman’s disease.  In solid organ recipients the incidence is greater in patients who are males, older age, travel or reside in Africa or the Middle East, are mismatched at the HLA-B locus and who have been treated with  antilymphocyte globulin.  In the US the incidence has been reported as 8.8 cases/ 100,000 person years.  KS most commonly affects the skin (90% of cases) whereas visceral involvement occurs in only about 25% of kidney transplant recipients.  PEL is a rare form of non-Hodgkin’s lymphoma which can either present as lymphomatous involvement of serosal serfaces (classic PEL) or tissue-based tumors with a poor prognosis (solid PEL).  Cells can be HHV-8 postitive or HHV-8/EBV double-positive.  Only few case reports have been documented in solid organ recipients.  Castleman’s disease is characterized by IL-6 overexpression which results in lymph node hyperplasia either unicentric, or multicentric.  Patients usually present with lymphadenopathy, effusions, higher fevers and may even has concomitant KS lesions.  Again, this complication is very rare in solid organ transplant recipients. 
Diagnosis
Serology has limited utility.  Antibodies can be detected against the latent phase antigen LANA-1 or the lytic antigen (ORF65 and K8.1) which correlate better with high HHV-8 viral loads.  HHV-8 DNA quantification in plasma and PBMC’s can also be performed.  In addition, immunohistochemical staining can be performed on human tissue confirming active infection. 
Treatment
The major treatment of HHV-8 is reduction of total immunosuppression.  Sirolimus also has been used for the treatment of KS and other HHV-8 disease.  If there is no improvement with the above strategies chemotherapy such as CHOP has also been employed.  Castleman’s disease can be cured with surgical excision if unicentric, while treating multicentric disease may entail therapy with rituximab, anti-IL6 receptor antibodies  and antiviral medications.  Of the antiviral agents, ganciclovir, foscarnet and cidofovir have in vitro activity against HHV-8 making them a potential treatment or prevention modality.  Unfortunately good in vivo and prospective data on treatment and prevention does not exist. 

In summary, HHV-8 is an important etiologic agent for transplant associated complications/ malignancies especially for those from endemic regions.  A variety of diagnostic and therapeutic treatments exist though recognition of the clinical syndrome and reduction of immunosuppression remain the cornerstones of treatment. 




Post by Dr. Vinay Nair

Thursday, October 6, 2011

IN THE News: A report about inducing tolerance in kidney transplants

A nice letter from investigators at Stanford published this week in NEJM Oct 2011 issue shows a proof of concept. 12 patients, got a HLA matched kidney and a donor cell infusion of CD34+ progenitor cells mixed with CD3+ T cells and irridiation and anti thymoglobuliun. The irridiation was not total body but more to spleen, thymus and lymph nodes. Giving stem cell transplantation and kidney transplant to a well matched patient led to chimerism and ultimately majority patients came off immunosuppresion and renal function is stable. Take a look at the full letter at





Thursday, September 29, 2011

TOPIC DISCUSSION: SIROLIMUS , not all that benign

The complications that can occur with use of sirolimus are not that benign. The agent is good in certain cases but not all. Besides the known side effects of FSGS, proteinuria and TMA in the kidney, there are other non renal side effects that one needs to be aware of.
1. Leukopenia, Anemia, Thrombocytopenia
2. Impaired wound healing
3. Mouth Ulcers
4. Oligospermia
5. Interstitial Pneumonitis
6. Hyperlipidemia( all increased LDL, HDL and VLDL)
7. Hyperglycemia

Remember to monitor especially for lipids and glycemic control


Friday, September 23, 2011

Topic Discussion: Diabetic Nephropathy Post Kidney Transplantation

Post Transplant Porteinuria: Differential Diagnosis:
1. Recurrent Glomerular Disease
2. Denovo Glomerular Disease
3. Antibody Mediated Rejection
4. Infection from CMV or Adenovirus
5. Collapsing Glomerulopathy
6. Thrombotic Microangiopathy
7. Diabetic Nephropathy

What is the data and incidence on Diabetic Nephropathy Post transplant? 


80-100% of diabetics who undergo transplant will have histological changes of diabetic nephropathy, which may be seen within 6 years. Diabetic nephropathy is not believed to be a significant cause of allograft failure, but has not been well-studied. 

•One study that looked at a 5 year prospective trial of 48 pts with type-1 DM underwent renal transplant 
•Patients were randomized to intensive or standard insulin therapy (insulin several times per day/continuous vs 1-2 times daily); statistically significant difference in A1C maintained . The five year  post-transplant biopsy showed standard group had 2x increased volume of mesangial matrix (p=0.024) and 3x increase in arteriolar hyalinosis, wider basement membrane(p < 0.10). 
Understudied disease but by far the MOST common cause of proteinuria years following a kidney transplantation.

Post by Prasanth Krish, MD
Renal Fellow, Hofstra NSLIJ

Ref:

Tuesday, August 9, 2011

IN THE NEWS: Rituximab Targeting Podocytes in Recurrent FSGS

Rituximab might be working in a non B cell mediated manner in FSGS recurrence post transplant.
A new study by Fornoni et al showed this in an elegant way.
Some summary points

1. 41 patients were studied, post transplant and 14 were controls and remaining received rituxian as part of their induction.
2. Fewer podocytes with SMPDL-3b protein in biopsies from recurrent FSGS were found.
3. Serum from patients with recurrent FSGS had a decrease in both SMPDL -3b and sphingomyelinase activity.
4 They predicated that rituximab preserves SMPDL-3b expression in podocytes.
5.The above part was prevented with anti CD20 treatment.
6. They studied SMPDL-3b protein, cytoskeleton remodeling in cultured normal human podocytes that had been exposed to patient sera with or without rituximab.
7. Over-expression of SMPDL-3b or treatment with Anti CD20 was able to prevent recurrent FSGS and showed preservation of cytoskeleton.
8.These data suggest that modulation of the sphigolipid related proteins might be playing a role in causing recurrent FSGS and perhaps anti CD20 agents are inhibiting this process in a B cell independent fashion.

Key: SMPDL= sphingomyelin phosphdiesterase acid like.

ref:
http://www.ncbi.nlm.nih.gov/pubmed/21632984


Wednesday, June 15, 2011

Human Herpes Virus – 6: An uncommon but potentially treatable infectious agent in transplant recipients


HHV-6 is a DNA virus part of the beta-herpesvirus family andcan be divided into HHV-6 A and B. Primary infection is mild and occurs usually in childhood; therefore themajority of healthy adults have serologic evidence of prior infection.  HHV-6 can re-activate in theimmunocompromised transplant recipient leading to asymptomatic viralreplication or less commonly active infection. The highest prevalence by pcr has been shown to occur in bone marrowtransplant recipients (28% to 75%) but viral replication has also been shown tooccur in liver (28% to 32%) and renal transplant recipients (23% to 36%).  Although asymptomatic viremia is common,clinically active infection carries a high mortality and may be susceptible tospecific antiviral treatments.   
How does HHV-6infection present?
HHV-6 infection commonly presents with high fever oftenassociated with leukopenia, and encephalitis between 2-4 weeks posttransplantation.  Other clinicalmanifestations include pneumonitis, hepatitis, colitis and bone marrowsuppression.  Rash typical of a leukocytoclasticvasculitis can also be seen. Encephalitis may be associated with seizure activity andhyponatremia.  Encephalitis is morecommonly seen in BMT patients but has been described in solid organ transplantpatients as well.  HHV-6 infectionscommonly co-exist with other viral infections including CMV. 
HHV-6 reactivation has also been associated with druginduced hypersensitivity syndromes, malignancies, multiple sclerosis, fulminanthepatitis and mycocarditis though causality has not been demonstrated.
What are theassociated laboratory and imaging findings?
CBC: Bone marrow suppression, leucopenia, thrombocytopenia
Chemistry: Transaminitis, hyponatremia
CSF:  High lymphocytecell count with elevated protein.  HHV-6can be detected in CSF by pcr. 
MRI of brain: Symmetric non-enhancing white matter lesions.  MRI may be normal in patients infected withHHV-6.
How can youdiagnose active infection?
Serologic testing: Sensitivity varies and most tests cross react with HHV-7.  A fourfold increase in titers orseroconversion is considered diagnostic.
Virus culture from affected tissue or blood can be done butare difficult to perform.
Viral detection: Virus may be present in PMBC’s of patients with latent infection leadingto a “false” positive pcr.   ThereforeHHV-6 should be identified in affected tissue or acellular plasma orserum. 
What are thetreatment options?
No therapy has been clearly documented to treat HHV-6although several agents with in-vitro activity have been tried.  Ganciclovir is effective against HHV-6B butmay not be active against HHV-6A (minority of infections).  Foscarnet has activity against both A and Bhowever; its use is complicated by nephrotoxicity.  In severe cases both agents can be tried andwhenever possible a reduction in immunosuppression should be considered.

References:
http://www.ncbi.nlm.nih.gov/pubmed/11241800                     

By
Dr. Vinay Nair

Friday, May 20, 2011

Alemtuzumab for Induction- the 2011 update

A recent NEJM May 2011 article has one article that compares use of Alemtuzumab and early steroid removal to Basiliximab and Thymo.  Its a nicely done randomized controlled trial that is multi centered.
On face value:- appears that rate of biopsy confirmed acute rejection was lower in the alemtuzumab group in the low risk patients when compared to basiliximab and similar to thymo when compared in high risk groups.

Few points from the trial:
1. All were steroid sparing making things not standard around all programs
2. The infection events were statistically more higher in the Alemtuzumab group especially in the low risk population
3. WBC count was also <3000 in the treatment arm
4. Cancer, renal injury other complications were similar
5. Rate of late rejection (after 12 months) was higher in both low and high risk groups compared to standard treatment
6. If steroids were withdrawn, and infections were more in the alemtuzumab group, wonder what the rate of infection would have been with steroids!

Till further studies, looking ahead. Awaiting to see what the transplant community thinks

Ref:
http://www.ncbi.nlm.nih.gov/pubmed/21591943
http://www.ncbi.nlm.nih.gov/pubmed/21591949

Monday, April 25, 2011

Dichotomous Effects of Rapamycin

A recent review in AJT 2011 April issue reviews this concept nicely.

Rapamycin has many faces and many different effects on different cells. Lets summarize
1. Suppression of CD4 T+ differentiation
2. Increased T reg development
3. Decreased response to skin graft
4. Decreased dendritic cell maturation
5. Increased CD8 + T cell  memory differentiation
6. Increased CD8 T cell activation
7. Increased response to pathogen
8. Increased IL-12 production

Commonly noted side effects:- hyperlipidemia, thrombocytopenia, decreased wound healing
Ref and information obtained from:
http://www.ncbi.nlm.nih.gov/pubmed/21446969

Wednesday, April 13, 2011

Transplant Tourism and Malignancy

Transplant Tourism does still continue and many patients continue to get kidneys from other countries where it could be commercial possible.  A recent study showed that when groups were compared( tourism kidneys to home country based kidneys):- the graft and patient survivals were equal but the 10 year cumulative cancer risk was significantly higher in the transplant tourism kidneys; especially in the older age group.  What might be contributing to this? - immunosuppresive therapy, difficulty in follow ups and were some of the thoughts mentioned in this article. Check it out


Ref:
http://www.ncbi.nlm.nih.gov/pubmed/21270768

Saturday, April 2, 2011

Neutropenia from Tacrolimus


Post transplant neutropenia has many causes.  Etiology is usually medications, infections, cancer.
In a retrospective evaluation, 28% neutropenia was noted after first year of transplantation.  Most of this was sought to be from MMF-tacrolimus combination.
The drugs we usually consider are: MMF, azathioprine, acyclovir, gancyclovir, bactrim, valcyte.
A recent review on CJASN 2011, presents three patients with pure tacrolimus induced neutropenia and the mechanism behind it. All improved after they were switched to cyclosporine.

Why does it happen?
1. Direct inhibition of myeloid cells
2. effect of the drug on mononuclear accessory cells
3. pharmacokinetic interaction between MMF and tacrolimus
4. autoantibodies against myeloid precursors or mature neutrophils

Ref:
http://www.ncbi.nlm.nih.gov/pubmed/21258040
http://www.ncbi.nlm.nih.gov/pubmed/19538494

Wednesday, March 23, 2011

Tuesday, March 15, 2011

Hematuria Post Kidney Transplantation

An entity often not talked about and not much out there in the literature. a nice review below by Dr.Krish.


All Posts

Search This Blog